BM Blokhin*, IP Lobushkova, AS Suyundukova and AD Prokhorova
Department of Outpatient and Emergency Paediatrics, Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia
*Corresponding Author: BM Blokhin, Department of Outpatient and Emergency Paediatrics, Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia.
Received: May 24, 2021; Published: June 30, 2021
Introduction: The article contains the results of a non-interventional, multicentre, prospective, observational, non-randomized clinical trial evaluating the efficiency and safety of Stodal drug product in children aged 2 to 7 years old with cough caused by acute respiratory infection (ARI).
Objective of the Research: To assess therapeutic efficiency and safety of Stodal drug product in children treated for cough caused by mild to moderate acute respiratory infections.
Materials and Methods: The study included 1000 children aged 2 to 7 years old with cough caused by mild to moderate ARI. The study was conducted in 23 medical institutions based in Moscow and the Moscow region. The study participants were stratified by age into 2 groups: Group 1 included children aged 2 to 4 years old; Group 2 included children aged 4 to 7 years old. Stodal clinical efficiency was evaluated based on the time course of cough severity in the daytime and at night, parents’/adoptive parents' satisfaction with the treatment and the treatment safety. Treatment duration was 7 days.
Results: In both groups, on the 7th day of therapy, treatment with Stodal resulted in a statistically significant decrease in cough severity: in Group 1, cough severity decreased by 1.51 (from 2.16 to 0.65; p < 0,001); in Group 2 it decreased by 1.57 (from 2.25 to 0.68; p < 0.001). Treatment efficiency was not age-dependent and was similar in both groups (p = 0.158). In total population cough severity in the daytime statistically significantly decreased by 1.53 (from 2.2 on the 1st day of treatment to 0.67 points on the 7th day of treatment, p < 0.001). In 35% of patients cough completely resolved (cough severity decreased to 0 points), and in 63% it became clinically insignificant (cough severity was 1 point). These children recovered and were allowed to attend organized groups. In Group 1, nocturnal cough severity statistically significantly decreased by 1.16 (from 1.64 to 0.48, p < 0.001); in Group 2 it decreased by 1.25 (from 1.71 to 0.46, p < 0.001). 951 (95,1%) parents/adoptive parents positively rated cough treatment and scored it using satisfaction rating scale as 4 and 5 points.
Conclusion: The study demonstrated efficiency and safety of Stodal drug product when used for cough treatment in children aged 2 to 7 years old with mild to moderate ARI, which allows to recommend Stodal to be included in treatment regimens beginning from the first days of the disease.
Citation: BM Blokhin., et al. “Cough Treatment Options in Children with Acute Respiratory Infections".Acta Scientific Nutritional Health 5.7 (2021): 107-117.
Copyright: © 2021 BM Blokhin., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.